Last reviewed · How we verify
Restoril — Competitive Intelligence Brief
marketed
Benzodiazepine [EPC]
Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2
Neuroscience
Live · refreshed every 30 min
Target snapshot
Restoril (temazepam) — Mallinckrodt.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Restoril TARGET | temazepam | Mallinckrodt | marketed | Benzodiazepine [EPC] | Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2 | |
| Onfi | CLOBAZAM | Lundbeck Pharms Llc | marketed | Benzodiazepine [EPC] | GABA-A receptor alpha-1/beta-2/gamma-2 | 2011-01-01 |
| Romazicon | FLUMAZENIL | marketed | Benzodiazepine Antagonist [EPC] | Gamma-aminobutyric acid receptor subunit alpha-5 | 1991-01-01 | |
| Prosom | ESTAZOLAM | Abbott | marketed | Benzodiazepine [EPC] | GABA-A receptor alpha-1/beta-2/gamma-2 | 1990-01-01 |
| Versed | midazolam | Generic (originally Roche) | marketed | Benzodiazepine (short-acting) | Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2 | 1985-12-20 |
| Versed | Midazolam Hydrochloride | Takeda Pharmaceutical Company Limited | marketed | Benzodiazepine | GABA A receptor alpha-5/beta-2/gamma-2 | 1985-01-01 |
| Xanax | alprazolam | Generic (originally Upjohn/Pfizer) | marketed | Benzodiazepine (triazolobenzodiazepine) | Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 | 1981-10-16 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Versed · 9687495 · Formulation · US
- — Versed · 9289432 · Formulation · US
- — Versed · 8217033 · Formulation · US
- — Versed · 8809322 · Formulation · US
- — Versed · 9687495 · Formulation · US
- — Versed · 9289432 · Formulation · US
- — Versed · 8217033 · Formulation · US
- — Versed · 8809322 · Formulation · US
- — Versed · 10966990 · Formulation · US
- — Versed · 10966990 · Formulation · US
- — Onfi · 12403090 · Formulation · US
- — Onfi · 12290597 · Formulation · US
- — Onfi · 11541002 · Formulation · US
Sponsor landscape (Benzodiazepine [EPC] class)
- Generic (originally Roche) · 2 drugs in this class
- · 2 drugs in this class
- Abliva AB · 1 drug in this class
- Mallinckrodt · 1 drug in this class
- Generic (originally Wyeth/Pfizer) · 1 drug in this class
- Lundbeck Pharms Llc · 1 drug in this class
- Abbott · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Restoril CI watch — RSS
- Restoril CI watch — Atom
- Restoril CI watch — JSON
- Restoril alone — RSS
- Whole Benzodiazepine [EPC] class — RSS
Cite this brief
Drug Landscape (2026). Restoril — Competitive Intelligence Brief. https://druglandscape.com/ci/temazepam. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab